EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review

Anna Svarna iD, Michalis Liontos iD, Alkistis Papatheodoridi iD, Aristea-Maria Papanota iD, Eleni Zografos iD, Maria Kaparelou, Flora Zagouri iD, Meletios-Athanasios Dimopoulos iD

Current Oncology · 25.04.2025 · 32 (5) · 251

DOI: 10.3390/curroncol32050251 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Current Oncology, online erschienen am 25.04.2025. Verfasst von Anna Svarna und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, V.Sofias 80, 11528 Athens, Greece. Hauptthemen laut MEDLINE: Uterine Neoplasms, Cystadenocarcinoma, Serous, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uterine serous carcinomas are an aggressive minority of endometrial cancers. They are characterized by mutations in TP53 and extensive copy number alterations and are primarily classified in the copy number-high/p53abn molecular prognostic group, highlighting a unique molecular profile that is crucial for understanding their behavior and treatment responses. Clinical studies have shown that molecular categorization via biomarkers can facilitate proper treatment selection, and this is now widely used. In this context, the scope of this systematic review is to identify molecular characteristics with prognostic significance for these neoplasms to further inform on their treatment needs. We performed a comprehensive literature search of all articles written in English using the PubMed/Medline and Cochrane databases through February 2025. Our review led to the inclusion of 95 studies, from which we identified a total of 66 distinct molecular characteristics along with new cancer signatures that may impact prognosis. These findings have the potential to inform clinical practice by aiding in the development of tailored treatment strategies for patients with uterine serous carcinoma, ultimately improving outcomes in this challenging malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsCystadenocarcinoma, SerousBiomarkers, TumorHumansFemalePrognosisTumor Suppressor Protein p53Mutation

Stichwörter der Autor:innen

biomarkersprognostic factorsserous uterine cancer

Substanzen

Biomarkers, TumorTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, V.Sofias 80, 11528 Athens, Greece.

ORCID-Profile: Anna Svarna, Michalis Liontos, Alkistis Papatheodoridi, Aristea-Maria Papanota, Eleni Zografos, Flora Zagouri, Meletios-Athanasios Dimopoulos

Zitieren

APA

Svarna, A., Liontos, M., Papatheodoridi, A., Papanota, A. M., Zografos, E., Kaparelou, M., Zagouri, F., & Dimopoulos, M. A. (2025). Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review. Current Oncology, 32(5), 251. https://doi.org/10.3390/curroncol32050251

Vancouver

Svarna A, Liontos M, Papatheodoridi A, Papanota AM, Zografos E, Kaparelou M, et al. Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review. Current Oncology. 2025;32(5):251. doi:10.3390/curroncol32050251

BibTeX
@article{Svarna2025,
  author = {Svarna, Anna and Liontos, Michalis and Papatheodoridi, Alkistis and Papanota, Aristea-Maria and Zografos, Eleni and Kaparelou, Maria and Zagouri, Flora and Dimopoulos, Meletios-Athanasios},
  title = {Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {5},
  pages = {251},
  doi = {10.3390/curroncol32050251}
}
Kostenlos starten →